IPSC — Century Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1850119 ·
Last close
$2.02
Market Cap
$364.32M
52W High
$2.55
52W Low
$1.96
ADV30
1,683,270
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -23,684,000 | -21,645,000 | 326,553,000 | 51,048,000 | 61,809,000 |
| Dec 2025 | 0 | — | -20,651,000 | -19,171,000 | 223,704,000 | 61,853,000 | 64,768,000 |
| Sep 2025 | 0 | — | -29,361,000 | -34,422,000 | 244,717,000 | 55,515,000 | 68,369,000 |
| Jun 2025 | 0 | — | -34,664,000 | -32,541,000 | 284,692,000 | 56,878,000 | 74,794,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-94,515,000
Investing CF
$-33,044,000
Financing CF
$126,676,000
CapEx
$-1,571,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-813,562,000
Inventory
—
Receivables
$667,000
ST Investments
$83,755,000
EBIT TTM
$-108,360,000
Pretax Income TTM
$-107,847,000
Interest Exp TTM
$0
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-101,596,000
Free Cash Flow
$-53,628,000
Enterprise Value
$308,199,040
Total Cash
$134,803,008
Total Debt
$48,025,000
Shares Out
180,354,809
Trailing EPS
$-1.14
Book Value
$1.47
ROE
-42.7%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,164,000 | -10,506,000 | -9,580,000 | 223,704,000 | 64,768,000 | — | -103,876,000 |
| Dec 2024 | 6,589,000 | -133,810,000 | -126,566,000 | 353,216,000 | 191,854,000 | — | -110,135,000 |
| Dec 2023 | 2,235,000 | -125,181,000 | -136,673,000 | 360,691,000 | 175,941,000 | — | -88,348,000 |
| Dec 2022 | 5,199,000 | -123,831,000 | -130,932,000 | 486,544,000 | 183,806,000 | — | 14,052,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | $375.39M | $3.98 | — |
| CCCC | C4 Therapeutics, Inc. | $384.77M | $3.48 | — |
| CMPX | Compass Therapeutics, Inc. | $343.97M | $1.91 | — |
| IKT | Inhibikase Therapeutics, Inc. | $342.33M | $2.18 | — |
| EDIT | Editas Medicine, Inc. | $395.93M | $2.58 | — |
News headlines (Yahoo Finance, 1h cache)
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
2026-07-14 10:33 · Yahoo
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
2026-07-09 12:00 · Yahoo
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
2026-06-22 17:00 · Yahoo
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
2026-06-13 13:38 · Yahoo
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
2026-06-10 18:22 · Yahoo
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
2026-06-08 20:05 · Yahoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
2026-05-14 12:00 · Yahoo
Century Therapeutics Reports First Quarter Financial Results and Business Updates
2026-05-13 12:00 · Yahoo
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
2026-05-01 08:18 · Yahoo
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
2026-04-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.